Physicochemical Properties
| Molecular Formula | C12H11N5O3 |
| Molecular Weight | 273.247441530228 |
| Exact Mass | 273.086 |
| CAS # | 2250288-69-6 |
| PubChem CID | 137628679 |
| Appearance | Light yellow to yellow solid powder |
| LogP | 0.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 20 |
| Complexity | 492 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C1C(CCC(N1)=O)N1C(C2C(=CC=CC=2N=N1)N)=O |
| InChi Key | DXZBHVQOULDEPN-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19) |
| Chemical Name | 3-(5-amino-4-oxo-1,2,3-benzotriazin-3-yl)piperidine-2,6-dione |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | NCI-H929 myeloma cell line proliferation is inhibited by TD-106 (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM; 72 hours) with a CC50 of 0.039 μM[1]. In NCI-H929 cells, TD-106 (1, 10, 100, and 1000 nM) causes IKZF1/3 to degrade [1]. |
| ln Vivo | Using a TMD-8 xenograft model, TD-106 (50 mg/kg; i.p.; qd for 14 days) exhibits antimyeloma action in SCID mice. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: NCI-H929 cells Tested Concentrations: 72 hrs (hours) Incubation Duration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM Experimental Results: Inhibited cell proliferation with an CC50 of 0.039 μM. |
| Animal Protocol |
Animal/Disease Models: Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model[1] Doses: 50 mg/kg Route of Administration: Intraperitoneally (ip); qd for 14 days Experimental Results: Treatment inhibited tumor growth during this duration . |
| References |
[1]. A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 125 mg/mL (~457.46 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6597 mL | 18.2983 mL | 36.5965 mL | |
| 5 mM | 0.7319 mL | 3.6597 mL | 7.3193 mL | |
| 10 mM | 0.3660 mL | 1.8298 mL | 3.6597 mL |